IBUPROFEN
Pain
Strength400 mg
Formoral.solid
Legg-Calve-Perthes disease belongs to the 4-to-10-year-old, so the weight-based child dose is the one in use. For an adolescent of 12 years or over, or an adult: 200 to 400 mg 3 to 4 times daily, to a maximum of 1,200 mg in 24 hours, taken with food. - Short courses during painful phases, not continuously through the two to four years the disease runs.
5-10 mg/kg/dose [child max 400 mg]
(Child over 3 months: 5 to 10 mg/kg 3 to 4 times daily, to a maximum of 30 mg/kg in 24 hours. Nothing under 3 months of age. A single dose is capped at 400 mg, which is the adult single-dose maximum in the same MSF entry.)
| 3kg | 15-30 mg/dose |
|---|---|
| 4kg | 20-40 mg/dose |
| 5kg | 25-50 mg/dose |
| 6kg | 30-60 mg/dose |
| 7kg | 35-70 mg/dose |
| 8kg | 40-80 mg/dose |
| 9kg | 45-90 mg/dose |
| 10kg | 50-100 mg/dose |
| 11kg | 55-110 mg/dose |
| 12kg | 60-120 mg/dose |
| 13kg | 65-130 mg/dose |
| 14kg | 70-140 mg/dose |
| 15kg | 75-150 mg/dose |
| 16kg | 80-160 mg/dose |
| 17kg | 85-170 mg/dose |
| 18kg | 90-180 mg/dose |
| 19kg | 95-190 mg/dose |
| 20kg | 100-200 mg/dose |
| 21kg | 105-210 mg/dose |
| 22kg | 110-220 mg/dose |
| 23kg | 115-230 mg/dose |
| 24kg | 120-240 mg/dose |
| 25kg | 125-250 mg/dose |
| 26kg | 130-260 mg/dose |
| 27kg | 135-270 mg/dose |
| 28kg | 140-280 mg/dose |
| 29kg | 145-290 mg/dose |
| 30kg | 150-300 mg/dose |
| 31kg | 155-310 mg/dose |
| 32kg | 160-320 mg/dose |
| 33kg | 165-330 mg/dose |
| 34kg | 170-340 mg/dose |
| 35kg | 175-350 mg/dose |
| 36kg | 180-360 mg/dose |
| 37kg | 185-370 mg/dose |
| 38kg | 190-380 mg/dose |
| 39kg | 195-390 mg/dose |
| 40kg | 200-400 mg/dose |
| 41kg | 205-400 mg/dose (upper capped) |
| 42kg | 210-400 mg/dose (upper capped) |
| 43kg | 215-400 mg/dose (upper capped) |
| 44kg | 220-400 mg/dose (upper capped) |
| 45kg | 225-400 mg/dose (upper capped) |
| 46kg | 230-400 mg/dose (upper capped) |
| 47kg | 235-400 mg/dose (upper capped) |
| 48kg | 240-400 mg/dose (upper capped) |
| 49kg | 245-400 mg/dose (upper capped) |
| 50kg | 250-400 mg/dose (upper capped) |
MSF Essential Drugs 2024 (ibuprofen oral monograph)
Most children with Legg-Calve-Perthes disease are managed without an operation at first, and the article's own list of initial measures is avoiding high-impact activity, relative weight-bearing restriction with crutches during painful phases, and short courses of a non-steroidal anti-inflammatory drug - ibuprofen is the example it gives - to reduce the pain and the synovitis. The article names the drug and no amount, so the amount is MSF's.
- Fever, redness, or raised inflammatory markers are not part of Perthes. Do not let an anti-inflammatory quieten the pain of a septic arthritis and delay it - the article's own differential for the limping child is transient synovitis, septic arthritis, juvenile idiopathic arthritis and a slipped capital femoral epiphysis.
- The medicine treats the pain, not the disease. What decides the outcome is how round the femoral head is at skeletal maturity, and the containment decisions belong to paediatric orthopaedics.
- Severe pain with markedly restricted hip movement is a reason to involve the specialist rather than to increase the dose - the article's answer there is short-term bed rest or in-hospital skin traction.
- Not for a child under 3 months. MSF also contra-indicates ibuprofen in allergy to any NSAID, peptic ulcer, coagulation defects, haemorrhage, surgery carrying a risk of major blood loss, severe renal or hepatic impairment, severe heart failure, severe malnutrition, uncorrected dehydration or hypovolaemia, and severe infection.
- Avoid in pregnancy. MSF contra-indicates it outright from the beginning of the sixth month and names paracetamol as the substitute. Short-term use while breast-feeding carries no contra-indication.
- Give with caution to an older or an asthmatic patient. Do not combine it with methotrexate, with an anticoagulant, or with another NSAID, and watch the combination with a diuretic or an ACE inhibitor - MSF's instruction there is to drink plenty of fluids to avoid renal failure.
- It may cause allergic reactions, epigastric pain, peptic ulcer, haemorrhage and renal impairment.
| Egyptian brand | Manufacturer | Indicative price |
|---|---|---|
| DAJUANOFEN 400 MG 20 F.C. TABS. | COPAD PHARMA | 5.00 EGP (0.25/unit) |
| FLABU 400MG 10 F.C.TAB. | DELTA PHARMA | 3.75 EGP (0.38/unit) |
| NOVA-PROFEN 400MG 30 F.C. TABLETS | SANOFI | 12.75 EGP (0.42/unit) |
| IBUPROFEN 400 MG 10 TAB. | SEDICO | 6.00 EGP (0.60/unit) |
| MAFO 400 MG 30 F.C.TABS | EIPICO | 42.00 EGP (1.40/unit) |
| BRUFEN 400 MG 30 TABS. | KAHIRA > ABBOTT LABORATORIES | 78.00 EGP (2.60/unit) |
| PROFUSOL 400MG 20 S.G CAPS. | EUROPEAN EGYPTIAN PHARM. IND. | 31.00 EGP |
| ANALGIPROF 400 MG 25 SACHETS | EVA PHARMA | 37.50 EGP |
| NOVA-PROFEN 100MG/5ML ORAL SUSP. 100ML? strength differs? different route - not oral solid | SANOFI | 2.25 EGP |
| BRUFEMOL-N SUSP. 60 ML? strength differs? different route - not oral solid | ARAB DRUG COMPANY (ADCO) | 4.50 EGP |